{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:52:00Z","timestamp":1782514320830,"version":"3.54.5"},"reference-count":32,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["441595227"],"award-info":[{"award-number":["441595227"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Chordomas are very rare malignant neoplasms of the bone occurring almost exclusively along the spine. As the tumours are thought to arise from notochordal remnants, the vast majority of chordomas express the TBXT gene, resulting in detectable nuclear amounts of its gene product brachyury. This T-Box transcription factor is commonly recognised as being essential in chordoma cells, and limiting TBXT expression is thought to be the key factor in controlling this tumour. Although the tumour is rare, distinct molecular differences and vulnerabilities have been described with regard to its location and the progression status of the disease, rendering it mandatory for novel cell lines to reflect all relevant chordoma subtypes. Here, we describe a novel chordoma cell line arising from the pleural effusion of a disseminated, poorly differentiated chordoma. This cell line, U-CH22, represents a highly aggressive terminal chordoma and, therefore, fills a relevant gap within the panel of available cell culture models for this orphan disease. CDK7 and CDK9 inhibition was lately identified as being effective in reducing viability in four chordoma cell lines, most likely due to a reduction in brachyury levels. In this study, we determined the capability of the CDK7 inhibitor THZ1 and the CDK1\/2\/5\/9 inhibitor dinaciclib to reduce TBXT expression at mRNA and protein levels in a broad range of nine cell lines that are models of primary, recurrent, and metastasised chordoma of the clivus and the sacrum.<\/jats:p>","DOI":"10.3390\/diagnostics14101028","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T03:24:48Z","timestamp":1715829888000},"page":"1028","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of CDK Inhibitors on TBXT Expression in Chordoma Cell Lines Including the First Stable Cell Line of a High-Grade Chordoma"],"prefix":"10.3390","volume":"14","author":[{"given":"Sarah","family":"Bette","sequence":"first","affiliation":[{"name":"Institute of Pathology, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Haase","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Nell","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grieser","sequence":"additional","affiliation":[{"name":"Institute of Radiology, University Hospital Augsburg, 86156 Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"von Baer","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schultheiss","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Marienfeld","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F. E.","family":"Barth","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6338-1857","authenticated-orcid":false,"given":"Kevin","family":"Mellert","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1757-7861.2009.00027.x","article-title":"Review of Current Treatment of Sacral Chordoma","volume":"1","author":"Chen","year":"2009","journal-title":"Orthop. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1007\/s00586-018-5764-0","article-title":"Chordoma: A Systematic Review of the Epidemiology and Clinical Prognostic Factors Predicting Progression-Free and Overall Survival","volume":"27","author":"Bakker","year":"2018","journal-title":"Eur. Spine J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2350\/09-01-0584.1","article-title":"Clinical and Histopathologic Features of Chordomas in Children and Young Adults","volume":"13","author":"Ridenour","year":"2010","journal-title":"Pediatr. Dev. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00292-017-0399-1","article-title":"Notochordale Tumoren: Benigne notochordale Tumoren und Chordome","volume":"39","author":"Barth","year":"2018","journal-title":"Pathologe"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/path.1711500110","article-title":"Immunohistological Study in Chordomas","volume":"150","author":"Coindre","year":"1986","journal-title":"J. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/path.1711640208","article-title":"Expression of Different Cytokeratin Subclasses in Human Chordoma","volume":"164","author":"Heikinheimo","year":"1991","journal-title":"J. Pathol."},{"key":"ref_7","first-page":"328","article-title":"WHO Classification of Tumours of Soft Tissue and Bone","volume":"Volume 5","author":"Fletcher","year":"2013","journal-title":"WHO Classification of Tumours of Soft Tissue and Bone"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"300624","DOI":"10.1016\/j.hpr.2022.300624","article-title":"Poorly Differentiated Chordoma","volume":"28","author":"Yang","year":"2022","journal-title":"Hum. Pathol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.ijrobp.2006.02.059","article-title":"Sacral Chordomas: Impact of High-Dose Proton\/Photon-Beam Radiation Therapy Combined with or without Surgery for Primary versus Recurrent Tumor","volume":"65","author":"Park","year":"2006","journal-title":"Int. J. Radiat. Oncol.*Biol.*Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.2011.35.3656","article-title":"Phase II Study of Imatinib in Advanced Chordoma","volume":"30","author":"Stacchiotti","year":"2012","journal-title":"JCO"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S1470-2045(14)71190-8","article-title":"Building a Global Consensus Approach to Chordoma: A Position Paper from the Medical and Patient Community","volume":"16","author":"Stacchiotti","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.20618","article-title":"Imatinib Mesylate in Chordoma","volume":"101","author":"Casali","year":"2004","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/PAS.0000000000000462","article-title":"Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases","volume":"39","author":"Miettinen","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41591-018-0312-3","article-title":"Small-Molecule Targeting of Brachyury Transcription Factor Addiction in Chordoma","volume":"25","author":"Sharifnia","year":"2019","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.xcrm.2020.100188","article-title":"Targeted Brachyury Degradation Disrupts a Highly Specific Autoregulatory Program Controlling Chordoma Cell Identity","volume":"2","author":"Sheppard","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1078-0432.CCR-22-1865","article-title":"Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes","volume":"29","author":"Bai","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_17","unstructured":"Organisation Mondiale de la Sant\u00e9, and Centre International de Recherche sur le Cancer (2020). Soft Tissue and Bone Tumours, OMS. [5th ed.]."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00401-010-0767-x","article-title":"Loss of SMARCB1\/INI1 Expression in Poorly Differentiated Chordomas","volume":"120","author":"Mobley","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_19","unstructured":"(2023, September 19). Disease Models. Available online: https:\/\/www.chordomafoundation.org\/researchers\/disease-models\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers","volume":"153","author":"Hoke","year":"2013","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting Transcription Regulation in Cancer with a Covalent CDK7 Inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-14-3270","article-title":"Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4\/6 Cell-Cycle Pathway","volume":"75","author":"Goerttler","year":"2015","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1038\/cddis.2013.101","article-title":"Apoptosis of Osteosarcoma Cultures by the Combination of the Cyclin-Dependent Kinase Inhibitor SCH727965 and a Heat Shock Protein 90 Inhibitor","volume":"4","author":"Fu","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a Novel CDK Inhibitor, Demonstrates Encouraging Single-Agent Activity in Patients with Relapsed Multiple Myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clbc.2013.10.016","article-title":"Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) versus Capecitabine in Patients with Advanced Breast Cancer","volume":"14","author":"Mita","year":"2014","journal-title":"Clin. Breast Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-19-0119","article-title":"Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7","volume":"79","author":"Hu","year":"2019","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","article-title":"CDK7 Inhibitors as Anticancer Drugs","volume":"39","author":"Sava","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shen, X., Kretz, A.-L., Schneider, S., Knippschild, U., Henne-Bruns, D., Kornmann, M., Lemke, J., and Traub, B. (2023). Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030928"},{"key":"ref_30","first-page":"1876","article-title":"Efficacy and Safety of Dinaciclib versus Ofatumumab in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"129","author":"Ghia","year":"2017","journal-title":"J. Am. Soc. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/path.4729","article-title":"EGFR Inhibitors Identified as a Potential Treatment for Chordoma in a Focused Compound Screen","volume":"239","author":"Scheipl","year":"2016","journal-title":"J. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.15252\/embr.201744201","article-title":"BRACHYURY Directs Histone Acetylation to Target Loci during Mesoderm Development","volume":"19","author":"Beisaw","year":"2018","journal-title":"EMBO Rep."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/10\/1028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:43:08Z","timestamp":1760107388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/10\/1028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["diagnostics14101028"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14101028","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}